Innovus Pharma to Exhibit Its FlutiCare® and AllerVarx™ Products at the American Thoracic Society Event in San Diego from Sunday, May 20, 2018 to Tuesday, May 22, 2018

Company Continues to Expand the Marketing and Sale of its Primary
Allergy Products

SAN DIEGO–(BUSINESS WIRE)–Innovus Pharmaceuticals, Inc. (“Innovus Pharma” or the “Company”) (OTCQB
Venture Market: INNV), an emerging commercial-stage pharmaceutical
company that delivers safe, innovative and effective over-the-counter
medicine and consumer care products to improve men’s and women’s health
and respiratory diseases, today announced that Robert Verfurth, the
Company’s Vice President, Sales and Marketing, will exhibit through a
booth the Company’s primary allergy products, FlutiCare® and AllerVarx™
from Sunday, May 20, 2018 to Tuesday, May 22, 2018 at the San Diego
Convention Center, 111 West Harbor Drive, San Diego, CA 92101.
Interested persons can learn more about the event at http://conference.thoracic.org.

“We are delighted to have our team exhibit our lead allergy products,
FlutiCare® and AllerVarx™ to the over 16,000 attendees expected at the
conference,” said Dr. Bassam Damaj, the President and Chief Executive
Officer of Innovus Pharma. “Our presentation at this show is part of the
Company’s expanded marketing and sales efforts of both products to
physicians and medical professionals who recommend allergy products and
related supplements to their patients.”

About FlutiCare®

Similar to Flonase® and ClariSpray®, FlutiCare® is approved for OTC by
the FDA for “Allergy Symptom Relief” and is indicated to “Temporarily
relieve these symptoms of hay fever or other upper respiratory allergies
including:

  • Nasal congestion
  • Runny nose
  • Sneezing
  • Itchy nose
  • Itchy, watery eyes”

About AllerVarx™

AllerVarx™ is a patented formulation produced in bilayer tablets with a
technology that allows a controlled release of the ingredients. The
fast-release layer allows the rapid antihistaminic activity of Perilla.
The sustained-release layer enhances Quercetin, Spirulina and Vitamin D3 bioavailability,
thanks to its lipidic matrix, and exerts anti-allergic activity spread
over time. For more information on the product please visit www.allervarx.com.

The trademark Flonase® is a registered trademark owned by
GlaxoSmithKline and the trademark ClariSpray® is a registered
trademark owned by Bayer.

About Innovus Pharmaceuticals, Inc.

Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer
goods and specialty pharmaceutical company engaged in the
commercialization, licensing and development of safe and effective
non-prescription medicine and consumer care products to improve men’s
and women’s health and vitality and respiratory diseases. Innovus Pharma
delivers innovative and uniquely presented and packaged health solutions
through its (a) OTC medicines and consumer and health products, which we
market directly, (b) commercial partners to primary care physicians,
urologists, gynecologists and therapists, and (c) directly to consumers
through our on-line channels, retailers and wholesalers. The Company is
dedicated to being a leader in developing and marketing new OTC and
branded Abbreviated New Drug Application (“ANDA”) products. The Company
is actively pursuing opportunities where existing prescription drugs
have recently, or are expected to, change from prescription (or Rx) to
OTC.

For more information, go to www.innovuspharma.com;
www.zestra.com;
www.ejectdelay.com;
www.myvesele.com;
www.urivarx.com;
www.sensumplus.com;
www.myandroferti.com;
www.beyondhumantestosterone.com;
www.getbeyondhuman.com;
www.trybeyondhuman.com;
www.recalmax.com;
www.prostagorx.com;
www.fluticare.com;
www.allervarx.com;
www.apeaz.com;
and www.diabasens.com.

Innovus Pharma’s Forward-Looking Safe Harbor:

Statements under the Private Securities Litigation Reform Act, as
amended: with the exception of the historical information contained in
this release, the matters described herein contain forward-looking
statements that involve risks and uncertainties that may individually or
mutually impact the matters herein described for a variety of reasons
that are outside the control of the Company, including, but not limited
to, projected revenues from the FlutiCare® and AllerVarx™ products,
estimated market for its products, and statements about achieving its
other development, growth, commercialization, financial and staffing
objectives. Readers are cautioned not to place undue reliance on these
forward-looking statements as actual results could differ materially
from the forward-looking statements contained herein. Readers are urged
to read the risk factors set forth in the Company’s most recent filing
on Form S-1, annual report on Form 10-K, subsequent quarterly reports
filed on Form 10-Q and other filings made with the SEC. Copies of these
reports are available from the SEC’s website or without charge from the
Company.

Contacts

Innovus Pharma Investor Relations
Randy Berholtz, +1 858-249-7865
ir@innovuspharma.com